Edition:
United States

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

186.07USD
4:00pm EDT
Change (% chg)

$1.78 (+0.97%)
Prev Close
$184.29
Open
$184.19
Day's High
$186.52
Day's Low
$184.19
Volume
407,827
Avg. Vol
473,570
52-wk High
$227.54
52-wk Low
$142.83

Latest Key Developments (Source: Significant Developments)

Alembic Pharmaceuticals Receives Tentative Approval For Bimatoprost Ophthalmic Solution From USFDA
Monday, 6 Aug 2018 01:23am EDT 

Aug 6 (Reuters) - Alembic Pharmaceuticals ::ALEMBIC PHARMACEUTICALS LTD - RECEIVED US FOOD & DRUG ADMINISTRATION TENTATIVE APPROVAL FOR BIMATOPROST OPHTHALMIC SOLUTION.ALEMBIC PHARMACEUTICALS LTD - BIMATOPROST OPHTHALMIC SOLUTION, 0.03% IS INDICATED TO TREAT HYPOTRICHOSIS OF EYELASHES.ALEMBIC PHARMACEUTICALS LTD - CURRENTLY IN LITIGATION WITH ALLERGAN IN NEW JERSEY COURT, LAUNCH OF PRODUCT WILL DEPEND ON OUTCOME OF LITIGATION.  Full Article

Allergan Q2 Non-GAAP Performance Net Income Per Share Of $4.42
Thursday, 26 Jul 2018 06:30am EDT 

July 26 (Reuters) - Allergan plc ::ALLERGAN REPORTS STRONG SECOND QUARTER 2018 RESULTS INCLUDING GAAP NET REVENUES OF $4.1 BILLION.Q2 GAAP LOSS PER SHARE $1.39.Q2 EARNINGS PER SHARE VIEW $4.13 -- THOMSON REUTERS I/B/E/S.COMPANY RAISES AND NARROWS FULL-YEAR 2018 NON-GAAP NET REVENUE AND NON-GAAP PERFORMANCE NET INCOME PER SHARE GUIDANCE.ALLERGAN BOARD OF DIRECTORS AUTHORIZES NEW $2.0 BILLION SHARE REPURCHASE PROGRAM.QTRLY NON-GAAP PERFORMANCE NET INCOME PER SHARE OF $4.42.Q2 EARNINGS PER SHARE VIEW $4.13, REVENUE VIEW $3.92 BILLION -- THOMSON REUTERS I/B/E/S.SEES 2018 LOSS PER SHARE $3.08 - $2.57.SEES 2018 ADJUSTED EARNINGS PER SHARE ABOUT $16.00 - $16.50.SEES Q3 2018 LOSS PER SHARE ABOUT $0.31 - $0.01.SEES Q3 2018 ADJUSTED EARNINGS PER SHARE ABOUT $3.80 - $4.10.SEES 2018 GAAP TOTAL NET REVENUE OF ABOUT $15.475 BILLION - $15.625 BILLION.SEES 2018 NON GAAP TOTAL NET REVENUE OF ABOUT $15.450 BILLION - $15.600 BILLION.SEES Q3 2018 TOTAL NET REVENUE ABOUT $3.750 BILLION - $3.900 BILLION.FY2018 EARNINGS PER SHARE VIEW $16.08, REVENUE VIEW $15.31 BILLION -- THOMSON REUTERS I/B/E/S.Q3 EARNINGS PER SHARE VIEW $3.90, REVENUE VIEW $3.77 BILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Allergan's Study In Chronic Migraine Receives Migraine Research Award At American Headache Society's 60Th Annual Scientific Meeting
Thursday, 28 Jun 2018 08:01am EDT 

June 28 (Reuters) - Allergan plc ::ALLERGAN'S STUDY IN CHRONIC MIGRAINE RECEIVES MIGRAINE RESEARCH AWARD AT THE AMERICAN HEADACHE SOCIETY'S 60TH ANNUAL SCIENTIFIC MEETING.  Full Article

Allergan Announced Official Launch Of TrueTear
Friday, 13 Apr 2018 08:01am EDT 

April 13 (Reuters) - Allergan plc ::ANNOUNCED OFFICIAL LAUNCH OF TRUETEAR.  Full Article

Allergan And Richter Say Bipolar I Depression Study Meets Main Goal
Tuesday, 3 Apr 2018 08:00am EDT 

April 3 (Reuters) - Allergan Plc - For Rgh-Md ::ALLERGAN AND RICHTER ANNOUNCE POSITIVE TOPLINE RESULTS FROM THIRD OF THREE PIVOTAL TRIALS OF CARIPRAZINE IN BIPOLAR I DEPRESSION.PRIMARY ENDPOINT WAS MET IN STUDY EVALUATING PATIENTS WITH ACUTE BIPOLAR I DEPRESSION TREATED WITH CARIPRAZINE 1.5 MG VERSUS PLACEBO.CARIPRAZINE WAS GENERALLY WELL TOLERATED IN TRIAL.PLANS TO INCLUDE DATA FROM ALL THREE PIVOTAL TRIALS IN CO'S SNDA TO U.S. FDA IN SECOND HALF OF 2018.MOST COMMONLY REPORTED ADVERSE EVENTS IN CARIPRAZINE GROUPS WERE AKATHISIA, RESTLESSNESS, NAUSEA, AND FATIGUE.EFFICACY OF CARIPRAZINE IN TREATMENT OF BIPOLAR I DEPRESSION HAS BEEN DEMONSTRATED IN THREE POSITIVE PIVOTAL TRIALS.53, PRIMARY AND KEY SECONDARY EFFICACY ENDPOINTS WERE MET FOR CARIPRAZINE 1.5 MG DOSE GROUP.  Full Article

Allergan Said To Weigh Options For Women's Health Unit - Bloomberg
Monday, 2 Apr 2018 03:53pm EDT 

April 2 (Reuters) - :ALLERGAN SAID TO WEIGH OPTIONS FOR WOMEN'S HEALTH UNIT BLOOMBERG, CITING SOURCES‍​ - BLOOMBERG, CITING SOURCES‍​.  Full Article

Amgen And Allergan Receive Positive CHMP Opinion For Abp 980
Friday, 23 Mar 2018 08:41am EDT 

March 23 (Reuters) - Allergan Plc ::AMGEN AND ALLERGAN RECEIVE POSITIVE CHMP OPINION FOR ABP 980 (BIOSIMILAR HERCEPTIN®) FOR THE TREATMENT OF THREE TYPES OF CANCER.AMGEN ‍RECOMMENDED FOR APPROVAL FOR SAME INDICATIONS AS HERCEPTIN​.AMGEN CHMP POSITIVE OPINION FOR ABP 980 WILL NOW BE REVIEWED BY EUROPEAN COMMISSION.  Full Article

Revance Therapeutics, Mylan Ireland Enter Collaboration Deal‍
Wednesday, 28 Feb 2018 04:17pm EST 

Feb 28 (Reuters) - Revance Therapeutics Inc <>::REVANCE THERAPEUTICS SAYS ‍CO, MYLAN IRELAND LIMITED ENTERED INTO COLLABORATION DEAL- SEC FILING​.REVANCE THERAPEUTICS - ‍MYLAN AGREED TO PAY CO NON-REFUNDABLE UPFRONT PAYMENT OF $25 MILLION WITH CONTINGENT PAYMENTS OF UP TO $100 MILLION.REVANCE THERAPEUTICS - ‍CONTINGENT PAYMENTS BASED UPON ACHIEVEMENT OF SPECIFIED MILESTONES, SPECIFIED, TIERED SALES MILESTONES OF UP TO $225 MILLION​.REVANCE THERAPEUTICS INC - ‍MYLAN WILL PAY REVANCE ROYALTIES ON SALES OF BIOSIMILAR IN MYLAN TERRITORIES​.REVANCE THERAPEUTICS - ‍MYLAN MAY ELECT TO HAVE DRUG PRODUCT MANUFACTURED BY ANOTHER PARTY.REVANCE THERAPEUTICS INC - CO GRANTED MYLAN EXCLUSIVE, LICENSE TO CO'S INTELLECTUAL PROPERTY RIGHTS FOR DEVELOPMENT, COMMERCIALIZATION OF BIOSIMILAR​.REVANCE THERAPEUTICS INC - CO WILL BE PRIMARILY RESPONSIBLE FOR NON-CLINICAL DEVELOPMENT ACTIVITIES, CLINICAL DEVELOPMENT ACTIVITIES IN N. AMERICA​.  Full Article

Mylan To Bring Biosimilar Of Botox To Market Through Collaboration With Revance Therapeutics
Wednesday, 28 Feb 2018 04:05pm EST 

Feb 28 (Reuters) - Mylan Nv ::MYLAN TO BRING A BIOSIMILAR OF BOTOX TO THE MARKET THROUGH A COLLABORATION AND LICENSE AGREEMENT WITH REVANCE THERAPEUTICS.MYLAN NV - ‍COLLABORATION AND LICENSE DEAL FOR DEVELOPMENT AND COMMERCIALIZATION OF A PROPOSED BIOSIMILAR TO BOTOX​.MYLAN NV - ‍COLLABORATION INCLUDES AN UPFRONT PAYMENT OF $25 MILLION TO REVANCE​.MYLAN TO BRING A BIOSIMILAR OF BOTOX TO THE MARKET THROUGH A COLLABORATION AND LICENSE AGREEMENT WITH REVANCE THERAPEUTICS.  Full Article

Mylan NV Defeats Allergan's Maneuver To Rent Tribal Sovereign Immunity To Avoid Restasis Patent Challenge
Monday, 26 Feb 2018 08:00am EST 

Feb 26 (Reuters) - Mylan NV ::MYLAN NV - ‍U.S. PTAB DENIED ST. REGIS MOHAWK TRIBE'S MOTION TO TERMINATE CO'S PATENT CHALLENGE REGARDING 6 PATENTS RELATED TO ALLERGAN'S RESTASIS​.  Full Article

Photo

Allergan says revenue from aesthetics unit may double by 2025

NEW YORK Allergan Plc said revenue from its medical aesthetics business could double by 2025, even as it faces increasing competition for its blockbuster wrinkle treatment, Botox.